The success of imatinib in chronic myeloid leukemia (CML) patients has triggered great interest in developing novel drugs targeting the chimeric proteins, including ALK [6], ROS1 [7], RET [8], MET [9] and NTRK [10] fusions. The gene discussed is ROS1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.